Abstract
The outcome of liver transplantation for hepatitis B has markedly improved in the last two decades. This commentary discusses the findings and limitations of a study by Hwang et al., which retrospectively examined the outcome of 639 adult patients who underwent living donor liver transplantation for hepatitis B. The authors reported a 5-year HBV recurrence rate of 7.3% and concluded that high-dose hepatitis B immunoglobulin (HBIG) monotherapy and rescue antiviral therapy is an effective way to prevent HBV recurrence after liver transplantation. With the availability of safe and effective antiviral agents associated with low rates of drug resistance, HBIG monotherapy is rarely used. The standard approach involves administration of antiviral therapy to suppress HBV replication before transplantation, followed by a combination of HBIG and antiviral therapy after transplantation. Combination prophylaxis permits the dose of HBIG to be reduced, which results in cost savings and reduces rates of HBV recurrence.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Samuel D et al. (1993) Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329: 1842–1847
Ghany MG et al. (1998) Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 27: 213–222
Roche B et al. (2003) HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 38: 86–95
Kim WR et al. (2004) Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 10: 968–974
Hwang S et al. (2008) Prevention of hepatitis B recurrence after living donor liver transplantation: primary high-dose hepatitis B immunoglobulin monotherapy and rescue antiviral therapy. Liver Transpl 14: 770–778
Yao FY et al. (2001) Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 34: 411–416
Schiff E et al. (2007) Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 13: 349–360
Lok AS and McMahon BJ (2007) Chronic hepatitis B. Hepatology 45: 507–539
Gane EJ et al. (2007) Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 132: 931–937
Wong SN et al. (2007) Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 13: 374–381
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
AS Lok declared that she has received grant/research support from Bristol-Myers Squibb, Gilead and GlaxoSmithKline. She is also a Consultant for Gilead. B Degertekin declared no competing interests.
Rights and permissions
About this article
Cite this article
Degertekin, B., Lok, A. What is the optimal regimen for preventing hepatitis B recurrence after liver transplantation?. Nat Rev Gastroenterol Hepatol 6, 68–69 (2009). https://doi.org/10.1038/ncpgasthep1339
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep1339
